Stroke is the second leading cause of death worldwide, claiming more than 130,000 lives each year in the United States alone. It’s also the leading cause of long-term disability. In 2010, the cost of health care, medications, and missed work in the U.S. was $73.7 billion. Stroke is not an old person’s disease either; it can strike at any age. Death rates are higher for African-Americans, Hispanics and Native Americans than whites.

Current treatment options for stroke are too little, too late. This is particularly true for blood clot-induced ischemic stroke—which account for 87 percent of strokes. It’s been almost 20 years since Activase® (altiplase/tPA) was launched as a treatment for ischemic stroke. Few patients benefit from Activase, mainly because they don’t get to the hospital in time for the drug’s narrow treatment window.

All this may be changing, and in the process, creating a unique opportunity. Zocere, Inc. is developing a post-stroke injectable drug designed to protect patients from brain injury by arresting the progression of neurological damage caused by reduced blood flow. Our goal is to reduce deaths, long-term disability and the financial impact of stroke. Thus far, our research is promising. If we are successful—and we are working hard at it—our drug will be the first and possibly only neuro-protectant injectable therapy in the market.

“There is a significant lack of effective stroke therapies. Filling the gap in treatment represents a significant opportunity for patients, physicians, drug developers, and investors.”

Wayne Laslie, CEO
Zocere, Inc.